It has been demonstrated that the RANTES blockade in CRC results in a decrease in cancer-associated fibroblasts (CAFs) [18], reduced tumor xenograft growth, decreased migration of CRC cells, reduced liver metastases, increased sensitivity to anti-PDGFR therapy, and decreased infiltration of Tregs [19,20]. The gene discussed is PDGFRB; the disease is cancer.